India’s First ATM for Early Diagnosis of Cardiac Risk Factors Launched at NHF Conclave, Health News, ET HealthWorld

New Delhi, 8th April 2022: Amid the rising incidence of Heart Failure in India, IMA NDB last week organized the National Heart Failure Conclave-2022 at Eros International Hotel, Nehru Place, New Delhi for discuss the evolution of breakthrough heart medicine pillars. failure and device therapy. More than 200 eminent physicians/cardiologists from Delhi/NCR attended the conclave and deliberated on different aspects of preventive cardiac care.

Health ATM screening hPoD, the first of its kind in India, developed by India Health Link (IHL) for early diagnosis of heart health risk factors introduced at National Heart Failure Conclave-2022 concluded week last. The IHL’s hPod (Fitness Station/Health Kiosk/Health ATM) is a non-invasive digitally integrated PHYGITAL (Physical+Digital) ecosystem, linking primary, preventive and predictive healthcare. Over 50 participating physicians were tested for 22 vital signs in less than 5 minutes and showed a sense of satisfaction, appreciating its convenient features that deliver the test report on the spur of the moment.

Founder and CEO of India Health Link (IHL), Dr. Satyender Goel says the incidence of heart attacks in India is increasing and preventive measures in terms of unique hPoD are in place which are instrumental in health care preventive heart disease. The “hPod” is a self-service ATM-sized health station, capable of screening (22) essential vital signs, including key metrics such as blood pressure, temperature, body mass composition, pulse , SPO2 and ECG, without any paramedical assistance. These key parameters are the main causes of heart failure and heart attacks. But the health TMJ characteristics brought by IHL have the technical insight that indicates upcoming metabolic disorders, which can be diagnosed and prevented early. The hPoD (Health ATM) is supposed to serve as a long-term preventative care.

Speaking at the conclave, Dr. Viveka Kumar, Chairman, IMA NDB and Senior Consultant, Cardiologist and Director of Max Heart and Vascular Institute, New Delhi shed light and said, “The power and promise of ARNI for the reduction in hospitalization for heart failure, and the reduction in the severity and worsening of heart failure is immense. And there is the need for device therapy and other interventions that can reduce if timely titrated ARNI therapy is instituted.

Dr HK Chopra, Chief Advisor, NHFC-2022, National Laureate, Science and Technology Communications, Past President, Cardiological Society of India, Senior Consultant Cardiologist, Medanta Moolchand, Heart Institute said: “There is a need for pro – Timely BNP NT and Echocardiographic assessment in heart failure patients as they are the cornerstone of management. SGLT2i reduces the need for diuretics and mechanical and surgical interventions and helps reverse morphological and functional remodeling of the heart, thereby increasing survival. Short- and long-term mortality benefits are documented worldwide on rapid intervention with ARNI and SGLT2i in heart failure.